iPSC-derived multiplex-engineered CD8αβT cells

iPSC-derived multiplex-engineered CD8αβT cells represent a next-generation, allogeneic cell therapy platform designed to overcome the limitations of autologous T cell therapies in cancer treatment. These induced pluripotent stem cell (iPSC)-derived CD8αβT cells are engineered with a multiplex knockout strategy targeting CISH and a key SOCS family member, both negative regulators of activation cytokine signaling, to drive functional persistence and lower activation thresholds. Additionally, apoptotic pathways are modulated to alleviate activation-induced cell death, enabling vigorous expansion and effector function even at physiological cytokine levels. The cells also incorporate an innovative signal converter (SC) module that, upon engagement with tumor targets, unleashes a synthetic costimulatory signal to selectively amplify iCD8αβT cell expansion within the tumor microenvironment. This combinatorial engineering delivers durable, tumor-specific cytotoxicity alongside intrinsic mechanisms of immune evasion. The platform can be armed with Chimeric Antigen Receptors (CARs), such as those targeting CD19, or T-cell Receptors (TCRs), like a KRAS G12V-specific TCR, to achieve antigen-specific, complete, and durable tumor clearance. The manufacturing process is proprietary, feeder-free, enrichment-free, and GMP-compliant, allowing for scalable and cost-effective production of ultra-pure CD8αβT cells for hematologic malignancies.

Other names

engineered iCD8αβT cellsiCD8αβT cells